Menu
Search
|

Menu

Close
X

CymaBay Therapeutics Inc CBAY.OQ (NASDAQ Stock Exchange Global Select Market)

10.12 USD
-- (--)
As of Oct 15
chart
Previous Close 10.12
Open --
Volume --
3m Avg Volume 246,941
Today’s High --
Today’s Low --
52 Week High 15.59
52 Week Low 7.63
Shares Outstanding (mil) 59.05
Market Capitalization (mil) 620.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
10
FY16
0
FY15
0
EPS (USD)
FY18
-0.614
FY17
-0.832
FY16
-1.137
FY15
-0.768
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
119.08
6.55
Price to Book (MRQ)
vs sector
3.11
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-45.97
12.83
Return on Equity (TTM)
vs sector
-47.49
14.95

EXECUTIVE LEADERSHIP

Robert Wills
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sujal Shah
President, Chief Executive Officer, Since 2017
Salary: $330,000.00
Bonus: $150,000.00
Charles McWherter
Senior Vice President, Chief Scientific Officer, Since
Salary: --
Bonus: --
Daniel Menold
Vice President - Finance, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Kirk Rosemark
Vice President - Regulatory Affairs and Quality Assurance, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7999 Gateway Blvd Ste 130
NEWARK   CA   94560-1188

Phone: +1510.2938800

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

SPONSORED STORIES